drugset / Trial / NCT05961709
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Phase 2
Active not recruiting
50 enrolled
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if cemiplimab can help to control dMMR colon cancer.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |